Publication:
[An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants].

Simple item page
dc.contributor.authorSánchez Luna, Manuel
dc.contributor.authorPérez Muñuzuri, Alejandro
dc.contributor.authorLeante Castellanos, José Luis
dc.contributor.authorRuiz Campillo, César W
dc.contributor.authorSanz López, Ester
dc.contributor.authorBenavente Fernández, Isabel
dc.contributor.authorSánchez Redondo, María Dolores
dc.contributor.authorRite Gracia, Segundo
dc.contributor.authoren representación de la Comisión de Estándares de la Sociedad Española de Neonatología
dc.date.accessioned2023-01-25T13:43:06Z
dc.date.available2023-01-25T13:43:06Z
dc.date.issued2019-10-01
dc.identifier.doi10.1016/j.anpedi.2019.08.003
dc.identifier.essn2341-2879
dc.identifier.pmid31585838
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.anpedi.2019.08.003
dc.identifier.urihttp://hdl.handle.net/10668/14586
dc.issue.number5
dc.journal.titleAnales de pediatria
dc.journal.titleabbreviationAn Pediatr (Engl Ed)
dc.language.isoes
dc.organizationHospital Universitario Puerta del Mar
dc.page.number348-350
dc.pubmedtypeLetter
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.meshAntiviral Agents
dc.subject.meshDrug Administration Schedule
dc.subject.meshHumans
dc.subject.meshInfant, Newborn
dc.subject.meshInfant, Premature
dc.subject.meshInfant, Premature, Diseases
dc.subject.meshNeonatology
dc.subject.meshPalivizumab
dc.subject.meshPractice Guidelines as Topic
dc.subject.meshRespiratory Syncytial Virus Infections
dc.subject.meshRisk
dc.subject.meshSocieties, Medical
dc.subject.meshSpain
dc.title[An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants].
dc.title.alternativeRecomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number91
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Puerta del Mar

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía